The BOPPP Trial
Using non-selective beta-blockers (NSBBs) to prevent complications of liver cirrhosis. Cirrhosis or liver scarring is a big problem in healthcare. In the United Kingdom, 60,000 people are living with cirrhosis. Sadly about 11,000 will die every year because of it....
Can AI work out the best dose of immunosuppressants after a liver transplant?
Machine learning is a type of AI. It is a developing and exciting tool which can be useful for making predictions. But can it be used to help guide the correct dose of medicines? For example, the immunosuppressant tacrolimus, which is used after liver transplants. A...
The PROMISE study
Faecal Microbiota Transplantation (FMT) to reduce susceptibility to infections resulting in hospitalisation for patients with liver disease. The human body creates inflammation to fight infection. Our gut contains trillions of bacteria (or bugs), often referred to as...
Green light for new liver cirrhosis trial using engineered immune cells
A new UK clinical trial will “supercharge” patients’ own immune cells to help their livers recover. The EMERALD trial (Evaluating Macrophages Engineered to Resolve Advanced Liver Disease), will see if people with advanced liver cirrhosis can benefit from...